A UCLA study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as ...
Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...
A new study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as the ...
a class of drug that effectively reduces cholesterol. Guidelines for doctors do not recommend prescribing statins to diabetic patients unless they have high cholesterol levels. But the new ...
Overall, a 20% decrease in LDL cholesterol was seen. Participants reported that they would have found more information on drug interactions ... make statins unavailable to non-insured or indigent ...
has submitted New Drug Submissions to Health Canada for two cholesterol-lowering medications, NEXLETOL and NEXLIZET, the company announced today. These oral, non-statin drugs are designed to ...
ANN ARBOR, Mich. - Esperion (NASDAQ: NASDAQ:ESPR), which has seen remarkable revenue growth of 187% over the last twelve months, has submitted New Drug Submissions to Health Canada for two cholesterol ...